{"id":22116,"date":"2023-02-10T21:27:00","date_gmt":"2023-02-10T13:27:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22116"},"modified":"2025-01-19T21:31:02","modified_gmt":"2025-01-19T13:31:02","slug":"astrazeneca-reports-q4-and-full-year-2022-results-with-strong-revenue-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22116","title":{"rendered":"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth"},"content":{"rendered":"\n

UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN<\/a>) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca’s strong pipeline and market presence.<\/p>\n\n\n\n

Q4 Performance and COVID-19 Impact<\/strong>
In the fourth quarter, the pace of expansion slowed to 2% YOY at USD 11.2 billion, impacted by falling sales of the COVID-19 vaccine Vaxzevria. Excluding Vaxzevria, total revenues were up 17%, with oncology product sales up 19%, cardiovascular, renal, and metabolism (CVRM) up 19%, respiratory and immunology (R&I) up 3%, and Rare Diseases growing at 10% YOY.<\/p>\n\n\n\n

2023 Outlook and Pipeline Strength<\/strong>
The expectation for 2023 is that COVID-19 revenues will dissipate, resulting in overall low-to-mid single-digit percentage growth. However, excluding COVID-19 medicines, revenues are forecast to continue to expand at low double-digit rates. CEO Pascal Soriot underlined AstraZeneca\u2019s continued pipeline strength, noting \u201ca record 34 approvals in major markets\u201d during 2022. The company aims to initiate \u201cmore than 30 Phase III trials this year, of which 10 have the potential to deliver peak year sales over USD 1 billion,\u201d while 15 new medicines should reach the market between now and the end of the decade.<\/p>\n\n\n\n

Leading Products and Sales Growth<\/strong>
Over the 12 months, the leading product globally was the non-small cell lung cancer (NSCLC) therapy Tagrisso (osimertinib) with USD 5.44 billion in sales, up 15% YOY. Other key cancer drugs included the PD-L1 targeted Imfinzi (durvalumab), PARP inhibitor Lynparza (olaparib), and BTK inhibitor Calquence (acalabrutinib), each generating over USD 2 billion in annual sales with double-figure growth, Calquence being the most impressive at 69% YOY expansion. Type 2 diabetes drug Farxiga (dapagliflozin) sales expanded by 56% to USD 4.4 billion, while from the rare disease portfolio, Soliris (eculizumab) brought in USD 3.76 billion (-5% YOY) and Ultomiris (ravulizumab) USD 1.97 billion (+42%).<\/p>\n\n\n\n

China Market Performance and Outlook<\/strong>
The China market was flat with zero reported growth at USD 5.79 billion in annual revenues, accounting for 13% of AstraZeneca\u2019s global revenues. In Q4, China market sales were up 3% to USD 1.194 billion. CFO Aradhana Sarin predicted during the earnings conference call that, \u201cIn China, we expect to return to growth in 2023 with 2022 having been more of a transition year due to pricing dynamics relating to VBP and NRDL.\u201d<\/p>\n\n\n\n

Product-Specific Highlights in China<\/strong>
There is reportedly ongoing rising demand for Tagrisso thanks to the March 2021 National Reimbursement Drug List (NRDL) price cut, with value growth expected to return during 2023. Lynparza was boosted by NRDL inclusion in March 2021 for ovarian cancer, while potassium binder Lokelma (sodium zirconium cyclosilicate) is now the market-leading drug in its class after gaining reimbursement from January 2022. In this year’s NRDL update, AstraZeneca benefited from the first-time inclusion of Orpathys (savolitinib), partnered with that drug\u2019s originator HutchMed, reimbursed as a treatment for MET mutated NSCLC. The UK firm also saw 6 drugs renew NRDL listings.<\/a>-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,27,871],"class_list":["post-22116","post","type-post","status-publish","format-standard","hentry","category-company","tag-astrazeneca","tag-az","tag-finanical-reports","tag-nasdaq-azn"],"yoast_head":"\nAstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca's strong pipeline and market presence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22116\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22116\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-10T13:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-19T13:31:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22116#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22116\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth\",\"datePublished\":\"2023-02-10T13:27:00+00:00\",\"dateModified\":\"2025-01-19T13:31:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22116\"},\"wordCount\":484,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"Finanical Reports\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22116#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22116\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22116\",\"name\":\"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-10T13:27:00+00:00\",\"dateModified\":\"2025-01-19T13:31:02+00:00\",\"description\":\"UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca's strong pipeline and market presence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22116#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22116\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22116#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth - Insight, China's Pharmaceutical Industry","description":"UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca's strong pipeline and market presence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22116","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22116","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-10T13:27:00+00:00","article_modified_time":"2025-01-19T13:31:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22116#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22116"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth","datePublished":"2023-02-10T13:27:00+00:00","dateModified":"2025-01-19T13:31:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22116"},"wordCount":484,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","Finanical Reports","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22116#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22116","url":"https:\/\/flcube.com\/?p=22116","name":"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-10T13:27:00+00:00","dateModified":"2025-01-19T13:31:02+00:00","description":"UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca's strong pipeline and market presence.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22116#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22116"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22116#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22116"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22116\/revisions"}],"predecessor-version":[{"id":22117,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22116\/revisions\/22117"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}